|
Real-time Estimate
Other stock markets
|
5-day change | 1st Jan Change | ||
| 351.64 USD | +0.49% |
|
+4.86% | +4.23% |
| 01-13 | Baird Adjusts Cencora Price Target to $415 From $392, Maintains Outperform Rating | MT |
| 01-12 | Cencora, Inc. Presents at 44th Annual J.P. Morgan Healthcare Conference, Jan-12-2026 09:00 AM |
| Capitalization | 67.88B 58.25B 54.24B 50.47B 94.19B 6,128B 102B 624B 245B 2,932B 255B 249B 10,742B | P/E ratio 2026 * |
24.6x | P/E ratio 2027 * | 21.4x |
|---|---|---|---|---|---|
| Enterprise value | 69.07B 59.27B 55.19B 51.36B 95.83B 6,236B 103B 634B 250B 2,983B 259B 254B 10,930B | EV / Sales 2026 * |
0.2x | EV / Sales 2027 * | 0.18x |
| Free-Float |
35.16% | Yield 2026 * |
0.65% | Yield 2027 * | 0.68% |
Last Transcript: Cencora, Inc.
| 1 day | +0.48% | ||
| 1 week | +4.86% | ||
| Current month | +4.23% | ||
| 1 month | +0.49% | ||
| 3 months | +10.15% | ||
| 6 months | +19.48% | ||
| Current year | +4.23% |
| 1 week | 333.79 |  | 352.29 |
| 1 month | 329.1 | | 352.29 |
| Current year | 329.1 | | 352.29 |
| 1 year | 236.68 | | 377.54 |
| 3 years | 147.48 | | 377.54 |
| 5 years | 100.71 | | 377.54 |
| 10 years | 68.38 | | 377.54 |
| Manager | Title | Age | Since |
|---|---|---|---|
Robert Mauch
CEO | Chief Executive Officer | 59 | 01/10/2024 |
James Cleary
DFI | Director of Finance/CFO | 63 | 09/11/2018 |
Pawan Verma
CTO | Chief Tech/Sci/R&D Officer | 50 | 04/11/2024 |
| Director | Title | Age | Since |
|---|---|---|---|
Lon Greenberg
BRD | Director/Board Member | 75 | 16/05/2013 |
Robert Mauch
BRD | Director/Board Member | 59 | 01/10/2024 |
D. Mark Durcan
CHM | Chairman | 64 | 01/10/2025 |
| Change | 5d. change | 1-year change | 3-years change | Capi.($) | ||
|---|---|---|---|---|---|---|
 | +0.49% | +4.86% | +48.13% | +114.46% | 67.88B | |
| -0.62% | -2.04% | +11.25% | +9.00% | 217B | |
| -0.21% | -0.35% | +15.16% | +22.40% | 127B | |
| +0.12% | +1.20% | -10.73% | -18.89% | 59.1B | |
| -1.41% | +2.03% | +26.41% | +93.87% | 55.55B | |
| -0.31% | +4.95% | - | - | 36.13B | |
| -0.77% | +1.26% | -13.82% | -36.73% | 27.18B | |
| +0.85% | +2.15% | +28.85% | +33.22% | 25.94B | |
| +1.19% | -3.72% | +5.77% | -34.23% | 23.78B | |
| -1.67% | -1.41% | -25.11% | +25.81% | 21.24B | |
| Average | -0.21% | +0.90% | +9.55% | +23.21% | 66.07B | |
| Weighted average by Cap. | -0.31% | +0.31% | +13.51% | +26.03% |
| 2026 * | 2027 * | |
|---|---|---|
| Net sales | 341B 292B 272B 253B 473B 30,750B 509B 3,129B 1,231B 14,710B 1,277B 1,251B 53,900B | 363B 311B 290B 270B 503B 32,751B 543B 3,332B 1,311B 15,667B 1,361B 1,333B 57,407B |
| Net income | 2.39B 2.05B 1.91B 1.78B 3.31B 216B 3.57B 21.94B 8.63B 103B 8.96B 8.78B 378B | 3.12B 2.68B 2.5B 2.32B 4.34B 282B 4.67B 28.7B 11.29B 135B 11.72B 11.48B 494B |
| Net Debt | 1.19B 1.02B 949M 884M 1.65B 107B 1.78B 10.92B 4.29B 51.32B 4.46B 4.36B 188B | -1.1B -944M -879M -818M -1.53B -99.29B -1.65B -10.1B -3.97B -47.5B -4.12B -4.04B -174B |
| Date | Price | Change | Volume |
|---|---|---|---|
| 15/01/26 | 352.08 $ | +0.61% | 89,301 |
| 14/01/26 | 349.93 $ | +1.17% | 759,963 |
| 13/01/26 | 345.88 $ | +1.09% | 1,163,056 |
| 12/01/26 | 342.16 $ | +1.93% | 1,013,173 |
| 09/01/26 | 335.69 $ | -0.01% | 916,997 |
Delayed Quote Nyse, January 15, 2026 at 07:11 pm
More quotes
Trader
This super rating is the result of a weighted average of the rankings based on the following ratings: Global Valuation (Composite), EPS Revisions (4 months), and Visibility (Composite). We recommend that you carefully review the associated descriptions.
Investor
This super composite rating is the result of a weighted average of the rankings based on the following ratings: Fundamentals (Composite), Global Valuation (Composite), EPS Revisions (1 year), and Visibility (Composite). We recommend that you carefully review the associated descriptions.
Global
This composite rating is the result of an average of the rankings based on the following ratings: Fundamentals (Composite), Valuation (Composite), Financial Estimates Revisions (Composite), Consensus (Composite), and Visibility (Composite). The company must be covered by at least 4 of these 5 ratings for the calculation to be performed. We recommend that you carefully review the associated descriptions.
Quality
This composite rating is the result of an average of the rankings based on the following ratings: Capital Efficiency (Composite), Quality of Financial Reporting (Composite), and Financial Health (Composite). The company must be covered by at least 2 of these 3 ratings for the calculation to be performed. We recommend that you carefully review the associated descriptions.
Quarterly revenue - Rate of surprise
- Stock Market
- Equities
- COR Stock
Select your edition
All financial news and data tailored to specific country editions
MarketScreener is also available in this country: United States.
Switch edition